Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

Table 3 Clinicopathological variables and expressions from FGFR1 to FGFR4 in IGC

		FGFR1			FGFR2			FGFR3			FGFR4
		Low	High	p	Low	High	p	Low	High	p	Low	High	p
	n	62	38		36	64		24	76		19	81
Age (years)
< 65	32	19	13	0.71	10	22	0.50	7	25	0.73	9	23	0.11
≥ 65	68	43	25	0.71	26	42	0.50	17	51	0.73	10	58	0.11
Gender
Female	13	5	8	0.073	3	10	0.37	3	10	1.00	1	12	0.45
Male	87	57	30	0.073	33	54	0.37	21	66	1.00	18	69	0.45
Main location
Middle or lower	84	53	31	0.61	32	52	0.32	19	65	0.53	15	69	0.50
Upper	16	9	7	0.61	4	12	0.32	5	11	0.53	4	12	0.50
Depth of invasion
Early (T1)	49	34	15	0.14	22	27	0.069	12	37	0.91	17	32	<0.001
Advanced (T2/3/4)	51	28	23	0.14	14	37	0.069	12	39	0.91	2	49	<0.001
LN metastasis
Negative (N0)	66	42	24	0.64	26	40	0.33	16	50	0.94	17	49	0.016
Positive (N1/2/3)	34	20	14	0.64	10	24	0.33	8	26	0.94	2	32	0.016
Stage
I	60	40	20	0.24	25	35	0.15	15	45	0.77	18	42	0.001
II/III/IV	40	22	18	0.24	11	29	0.15	9	31	0.77	1	39	0.001
Distant metastasis or recurrence
Negative	80	53	27	0.080	31	49	0.25	17	63	0.24	19	61	0.01
Positive	20	9	11	0.080	5	15	0.25	7	13	0.24	0	20	0.01
Peritoneal dissemination
Negative	93	59	34	0.42	34	59	1.00	21	72	0.35	19	74	0.34
Positive	7	3	4	0.42	2	5	1.00	3	4	0.35	0	7	0.34
Hematogenous metastasis
Negative	90	56	34	1.00	34	56	0.32	22	68	1.00	19	71	0.20
Positive	10	6	4	1.00	2	8	0.32	2	8	1.00	0	10	0.20
HER2 score
0–1	84	50	34	0.24	30	54	0.89	19	65	0.53	18	66	0.29
2–3	16	12	4	0.24	6	10	0.89	5	11	0.53	1	15	0.29

ISSN: 1477-7819